Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study

NCT06082492 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT06082492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06082492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study
Lead sponsor
Radboud University Medical Center
Phase
Not applicable
Overall status
Recruiting
Start date
March 19, 2024
Completion date
June 30, 2029
Enrollment
690 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii non-small cell lung cancer